Stada Australia and BioQ Pharma collaborate

Stada Pharmaceuticals Australia and BioQ Pharma have signed a strategic agreement to commercialize three ready-to-use infusion pharmaceuticals in Australia and New Zealand.

The three-product collaboration between Stada Australia, a subsidiary of Germany’s Stada Arzneimittel (SAZ: Xetra) and BioQ includes Ropivacaine ReadyfusOR, an opioid sparing post-surgical pain management therapy, as well as two other product candidates. Ropivacaine ReadyfusOR is a ready-to-use, single use infusion product, which is pre-filled by the manufacturer with 0.2% Ropivacaine. It is a self-contained drug and administration system for delivery at the point of care, activated by a single touch. Ropivacaine ReadyfusOR was recently approved by the Therapeutic Goods Administration (TGA).

“We are very excited about this new partnership and look forward to working with the Stada team to advance our mutual commercial ambitions in Australia and New Zealand,” said Josh Kriesel, president and chief executive of BioQ Pharma, a privately-held company.

Gary Clark, managing director of Stada Australia, commented: “Stada welcomes the opportunity to partner with BioQ to introduce these innovative, self-contained infusion pharmaceuticals to the Australian and New Zealand markets. The addition of these exciting products to our portfolio will enhance our reputation as a provider of quality healthcare, leading to improved patient outcomes.”